Zevra Therapeutics (ZVRA) Change in Cash (2014 - 2026)

Zevra Therapeutics (ZVRA) has 13 years of Change in Cash data on file, last reported at $33.2 million in Q1 2026.

• Quarterly Change in Cash rose 833.59% year-over-year to $33.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $58.3 million (up 1157.45% YoY) and the FY2025 annual result came in at $28.6 million, up 408.95% from the prior year.
• Change in Cash advanced to $33.2 million in Q1 2026, from $8.0 million in the prior quarter.
• In the past five years, Change in Cash ranged from a high of $33.2 million in Q1 2026 to a low of -$25.3 million in Q1 2023.
• A 5-year average of -$985352.9 and a median of -$220000.0 in 2023 frame the typical range for Change in Cash.
• Annual changes were most pronounced in 2024 — Change in Cash sank 9106.36% — and 2025, when it surged 1877.5%.
• Tracing ZVRA's Change in Cash over 5 years: stood at -$4.7 million in 2022, then jumped by 95.28% to -$220000.0 in 2023, then slumped by 9106.36% to -$20.3 million in 2024, then surged by 139.34% to $8.0 million in 2025, then jumped by 316.58% to $33.2 million in 2026.
• The last three Change in Cash figures came in at $33.2 million (Q1 2026), $8.0 million (Q4 2025), and $6.7 million (Q3 2025), per Business Quant data.